IP Library Granted Patent US 11,389,461
Granted Patent B2
US 11,389,461 · App. 17/383,770 · Granted Jul 19, 2022

Spironolactone aqueous compositions

Inventors: Anthony Pipho (Winterville, NC); Michael Paul DeHart (Winterville, NC)
Assignee: CMP DEVELOPMENT LLC
A61K31/585A61K9/0053A61K9/0095A61K9/20A61K47/02A61K47/10A61K47/12A61K47/24A61K47/36A61K9/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,461
App. No.
17/383,770
Granted
Jul 19, 2022
Kind
B2
Abstract

Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.

Claims (41)

1. A ready-to-use liquid formulation, comprising:

micronized spironolactone in an amount of about 5 mg/mL;

xanthan gum in an amount to provide a formulation viscosity of from 100 cP to 300 cP,

glycerin in an amount of from 18 mg/mL to 24 mg/mL;

a sufficient amount of a citrate buffer to maintain a pH of the formulation from 4.5 to 5.5 and

a water vehicle.

2. The ready-to-use liquid formulation of claim 1 , wherein the micronized spironolactone has a median volume particle size of not more than about 9.6 μm.

3. The ready-to-use liquid formulation of claim 1 , wherein the micronized spironolactone has a median volume particle size of about 3.6 μm to about 9.6 μm.

4. The ready-to-use liquid formulation of claim 1 , wherein the xanthan gum is present in an amount of from 1.3 mg/mL to 3.6 mg/mL.

5. The ready-to-use liquid formulation of claim 1 , wherein the xanthan gum is present in an amount of from 1.8 mg/mL to 3.6 mg/mL.

6. The ready-to-use liquid formulation of claim 1 , wherein the glycerin is present in an amount of from 18 mg/mL to 22 mg/mL.

7. The ready-to-use liquid formulation of claim 1 , wherein the citrate buffer is present in an amount of from about 10 mM to about 100 mM.

8. The ready-to-use liquid formulation of claim 1 , wherein the citrate buffer is present in an amount of from about 10 mM to about 100 mM and wherein the pH of the formulation ranges from 4.8 to 5.2.

9. The ready-to-use liquid formulation of claim 1 ,

wherein the citrate buffer comprises from 1.7 mg/mL to 2.4 mg/mL citric acid and from 3.6 mg/mL to 4.8 mg/mL sodium citrate.

10. The ready-to-use liquid formulation of claim 1 , wherein the formulation viscosity ranges from 130 cP to 170 cP.

11. The ready-to-use liquid formulation of claim 1 , wherein the spironolactone content is 100±10% of labeled content when stored under 25±° C. and 40% relative humidity for 12-months.

12. A ready-to-use liquid formulation, comprising:

micronized spironolactone in an amount of about 5 mg/mL;

xanthan gum in an amount to provide a formulation viscosity of from 100 cP to 300 cP,

a dispersing agent consisting of glycerin in an amount of from 18 mg/mL to 24 mg/mL;

a sufficient amount of a citrate buffer to maintain a pH of the formulation from 4.5 to 5.5 and

a water vehicle.

13. The ready-to-use liquid formulation of claim 12 , wherein the micronized spironolactone has a median volume particle size of not more than about 9.6 μm.

14. The ready-to-use liquid formulation of claim 12 , wherein the micronized spironolactone has a median volume particle size of about 3.6 μm to about 9.6 μm.

15. The ready-to-use liquid formulation of claim 12 , wherein the xanthan gum is present in an amount of from 1.3 mg/mL to 3.6 mg/mL.

16. The ready-to-use liquid formulation of claim 12 , wherein the xanthan gum is present in an amount of from 1.8 mg/mL to 3.6 mg/mL.

17. The ready-to-use liquid formulation of claim 12 , wherein the glycerin is present in an amount of from 18 mg/mL to 22 mg/mL.

18. The ready-to-use liquid formulation of claim 12 , wherein the citrate buffer is present in an amount of from about 10 mM to about 100 mM.

19. The ready-to-use liquid formulation of claim 12 , wherein citrate buffer is present in an amount of from about 10 mM to about 100 mM and wherein the pH of the formulation ranges from 4.8 to 5.2.

20. The ready-to-use liquid formulation of claim 12 , wherein the citrate buffer comprises from 1.7 mg/mL to 2.4 mg/mL citric acid and/or from 3.6 mg/mL to 4.8 mg/mL sodium citrate.

21. The ready-to-use liquid formulation of claim 12 , wherein the formulation viscosity ranges from 130 cP to 170 cP.

22. The ready-to-use liquid formulation of claim 12 , wherein the spironolactone content is 100±10% of labeled content when stored under 25±° C. and 40% relative humidity for 12-months.

23. The ready-to-use liquid formulation of claim 1 , wherein the formulation viscosity ranges from 120 cP to 170 cP.

24. The ready-to-use liquid formulation of claim 1 , wherein the formulation viscosity ranges from 150 cP to 170 cP.

25. The ready-to-use liquid formulation of claim 1 , wherein the xanthan gum is from 1.3 mg/mL to 3.0 mg/mL.

26. The ready-to-use liquid formulation of claim 1 , wherein the micronized spironolactone has a median volume particle size of about 3.6 μm.

27. The ready-to-use liquid formulation of claim 12 , wherein the formulation viscosity ranges from 120 cP to 170 cP.

28. The ready-to-use liquid formulation of claim 12 , wherein the formulation viscosity ranges from 150 cP to 170 cP.

29. The ready-to-use liquid formulation of claim 12 , wherein the xanthan gum is from 1.3 mg/mL to 3.0 mg/mL.

30. The ready-to-use liquid formulation of claim 12 , wherein the micronized spironolactone has a median volume particle size of about 3.6 μm.

Assignments (6)
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Jan 21, 2025
From: FIRST HORIZON BANK, F/K/A FIRST TENNESSEE BANK, N.A.
To: TEXAS CAPITAL BANK
Reel/Frame 069967/0622 →
SECURITY INTEREST Recorded Jul 5, 2023
From: CMP DEVELOPMENT LLC
To: FIRST HORIZON BANK
Reel/Frame 064152/0199 →
SECURITY INTEREST Recorded May 18, 2022
From: CMP PHARMA, INC.; CMP ACQUISITION COMPANY LLC; CMP DEVELOPMENT LLC
To: FIRST HORIZON BANK FKA FIRST TENNESSEE BANK NATIONAL ASSOCIATION
Reel/Frame 059948/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: PIPHO, ANTHONY
To: CMP DEVELOPMENT LLC
Reel/Frame 058069/0997 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: DEHART, MICHAEL PAUL
To: MAYNE PHARMA, INC., DBA METRICS CONTRACT SERVICES
Reel/Frame 058070/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: MAYNE PHARMA, INC., DBA METRICS CONTRACT SERVICES
To: CMP DEVELOPMENT LLC
Reel/Frame 058070/0257 →
Continuity (8)
Continuation 17111578 · Dec 4, 2020
Continuation 16878092 · May 19, 2020
Continuation 16823604 · Mar 19, 2020
Continuation 16682477 · Nov 13, 2019
Continuation 15665014 · Jul 31, 2017
Continuation In Part 15337559 · Oct 28, 2016
Provisional Application 62495583 · Oct 30, 2015
Related Publication 20210346404A1 · Nov 11, 2021